Nanopublications

Matches in Nanopublications for { ?s ?p "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

Showing items 1 to 10 of 10 with 100 items per page.

NP337523.RAwQSki_9fKo7UHvLl0TB9d8SoiIch6JubQOlQJeLvVQw130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP337523.RAwQSki_9fKo7UHvLl0TB9d8SoiIch6JubQOlQJeLvVQw130_provenance.
NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP474602.RAU1qE6ihabf9LJ6zg7r-hUTouSu1IDIiJYw3l_Sg6zSs130_provenance.
NP618249.RA9Iyj0_q8evgRfQCpdTbAhvPg74B7fHZcr3KFwQPEzRQ130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618249.RA9Iyj0_q8evgRfQCpdTbAhvPg74B7fHZcr3KFwQPEzRQ130_provenance.
assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP299270.RAVs8HkukK5uNAWcBQwzCVec5Xpx4jQ8f8UahpNWAlgMM130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP299270.RAVs8HkukK5uNAWcBQwzCVec5Xpx4jQ8f8UahpNWAlgMM130_provenance.
NP469773.RAEUqmrwPPCu0b60JsLJf0W9a3iw3XKsCYcoqFUGyDR3k130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP469773.RAEUqmrwPPCu0b60JsLJf0W9a3iw3XKsCYcoqFUGyDR3k130_provenance.
NP579708.RAIHWE-iDqB3oxq1V1pVTXNvzh1dZLiZbXdueuBN0l9rs130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP579708.RAIHWE-iDqB3oxq1V1pVTXNvzh1dZLiZbXdueuBN0l9rs130_provenance.
NP339556.RATV5TJs0GsEdf_2oudmRgXM5HK6rdGaRKFmrVcCR_lI0130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP339556.RATV5TJs0GsEdf_2oudmRgXM5HK6rdGaRKFmrVcCR_lI0130_provenance.
NP904734.RADmR8ninQ0tNDEfpKdm32943tadS3VBDQcXmn-KLek7c130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904734.RADmR8ninQ0tNDEfpKdm32943tadS3VBDQcXmn-KLek7c130_provenance.
NP339557.RAFtN_fJrR29FaxKlNudOmIJb60aqvtUVNwL8qSyADJSU130_assertion description "[Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RAR beta, 11% for GSTP1, 7% for p16(INK4A), 4% for DAPK, and 2% for MGMT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP339557.RAFtN_fJrR29FaxKlNudOmIJb60aqvtUVNwL8qSyADJSU130_provenance.